VIVE - Viveve Medical, Inc.
| Previous Close | 3.23 |
| Open | 3.20 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1000 |
| Day's Range | 3.15 - 3.32 |
| 52 Week Range | 1.60 - 5.95 |
| Volume | 223,625 |
| Avg. Volume | 207,770 |
| Market Cap | 102.653M |
| Beta (3Y Monthly) | 1.15 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.83 |
| Earnings Date | May 9, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.89 |
- GlobeNewswire•21 days ago
Viveve to Present at Ladenburg Thalmann 2018 Healthcare Conference
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the 2018 Ladenburg Thalmann Healthcare Conference on Tuesday, October 2nd at 10:00 AM ET in New York City. Mr. Durbin will provide an update on the company's development strategies and commercialization efforts in the United States and abroad. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.
- GlobeNewswire•last month
Viveve Appoints Two New Independent Board Members
Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced that Steve Basta and Karen Zaderej have joined the Viveve board of directors, effective today. “The substantive experience and skill sets of both Steve and Karen are valued and extremely pertinent to Viveve as the company continues the commercial growth of the Viveve® System and seeks regulatory approvals for its CMRF technology in new indications with high unmet needs in women’s health,” remarked Scott Durbin, Viveve’s chief executive officer and director. Mr. Basta currently serves as chief executive officer of Menlo Therapeutics, Inc., a late-stage biopharmaceutical company that develops and commercializes treatments for dermatologic and other chronic conditions.
- GlobeNewswire•last month
Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence
Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for authorization to begin LIBERATE-U.S., a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of the Company’s proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women.
- Thomson Reuters StreetEvents•last month
Edited Transcript of VIVE earnings conference call or presentation 9-Aug-18 9:00pm GMT
Q2 2018 Viveve Medical Inc Earnings Call
- GlobeNewswire•2 months ago
Viveve to Present at 20th Annual Rodman & Renshaw Global Investment Conference
Viveve Medical, Inc. ("Viveve") (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the 2018 Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC on Thursday, September 6th at 11:15 AM ET in New York City. Mr. Durbin will provide an update on the company's development strategies and commercialization efforts in the United States and abroad.
- Zacks Small Cap Research•2 months ago
VIVE: Sales Force Realignment Appears To Be Paying Dividends As Q2 U.S. Systems Sales Crush Prior Record
Viveve (VIVE) reported Q2 2018 financial results and provided a business update. While international sales faltered, falling 18% from the prior year, that overseas weakness was much more than offset by extraordinarily robust domestic sales. Strength of the U.S. business, which also saw big gains on treatment tip ASPs and resultant widening of related margins, was attributed to increased production following the sales force realignment.
- GlobeNewswire•2 months ago
Viveve Initiates LIBERATE-International Trial for Improvement of Stress Urinary Incontinence
Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, announced today the initiation of LIBERATE-International, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women. “Initiation of LIBERATE-International represents a significant advance in our pursuit of regulatory clearances for the treatment of SUI, a condition that effects an estimated 25-30 million women worldwide.
- GlobeNewswire•2 months ago
Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Company reports 80% growth in total quarterly revenue year-over-year Multiple clinical and regulatory milestones achieved for Viveve ® System ENGLEWOOD, Colo., Aug. 09, 2018-- Viveve Medical Inc., a medical ...
- ACCESSWIRE•2 months ago
Viveve Medical Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Viveve Medical Inc (NASDAQ: VIVE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern Time. ...
- GlobeNewswire•2 months ago
Viveve Announces FDA Approval to Continue VIVEVE II Clinical Study
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency’s approval was based on a determination that the company provided sufficient data to support continued subject enrollment in the trial and that there are no subject protection concerns that preclude continuation of the study.
- Zacks Small Cap Research•2 months ago
VIVE: FDA Warning Letter Should Weed-Out Imposters and Benefit VIVE
On July 30th FDA issued a Safety Communications letter warning against the use of “Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ of Vaginal Cosmetic Procedures”. The purpose of the letter is to “alert patients and health care providers that the use of energy-based devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function may be associated with serious adverse events. FDA notes that they are aware of certain device manufacturers that may be marketing for these purposes – none of which are approved for those indications.
- GlobeNewswire•2 months ago
Viveve to Announce Financial Results for Second Quarter 2018 and Host Conference Call
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, will announce financial results for the second quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial markets. The company will also host a live conference call and webcast to discuss these financial results and provide an update on corporate and commercial developments. The conference call may be accessed by dialing 1-833-255-2833 (domestic) or 1-412-902-6723 (international) or via live webcast at https://services.choruscall.com/links/vive180809.html.
- ACCESSWIRE•3 months ago
Free Technical Research on Abbott Laboratories and Three More Medical Equipment Equities
On Tuesday, July 03, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Tuesday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Viveve Medical Inc. (NASDAQ: VIVE), Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), and Align Technology Inc. (NASDAQ: ALGN). On Tuesday, shares in Englewood, Colorado headquartered Viveve Medical Inc. recorded a trading volume of 213,805 shares.
- Zacks Small Cap Research•4 months ago
VIVE: Compelling SUI Feasibility Study 6-Month Data. SUI LIBERATE RCTs On-Deck
Last week Viveve (VIVE) announced what we would characterize as potentially compelling 6-month data from its ongoing SUI 12-month feasibility study. Listed under clinicaltrials.org Identifier: NCT03066180, the single-arm, 36-subject study is being conducted at Dr. Bruce Allan’s Allan Centre (Dr. Allan was also the principal investigator for the VIVEVE I vaginal laxity/sexual function study) in Calgary, Canada. While only a single-arm feasibility study, it was clearly designed to be consistent with FDA's recommendations for SUI-device pivotal studies (FDA's guidance for Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence).
- Simply Wall St.•4 months ago
What Is Viveve Medical Inc’s (NASDAQ:VIVE) Share Price Doing?
Viveve Medical Inc (NASDAQ:VIVE), a medical equipment company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months.Read More...
- Zacks Small Cap Research•5 months ago
VIVE: Q1 Results: Disappointing But Not All Was Bad. Guidance Intact But That May Now Be More Challenging
Viveve (VIVE) reported Q1 2018 financial results and provided a business update. Despite what we’d characterize as a pretty disappointing start to the year, management reiterated their previously issued 2018 revenue guidance in the range of $22M (+44%) to $24M (+57%). VIVE indicated that realignment of the sales force/territories and a national sales meeting (which sidelined the entire sales force for a week) significantly impacted Q1 domestic sales results.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of VIVE earnings conference call or presentation 10-May-18 9:00pm GMT
Q1 2018 Viveve Medical Inc Earnings Call
